Reversing Doxorubicin Resistance with Aclacinomycin A
Author Information
Author(s): J.-M. Millot, T.D.W. Rasoanaivo, H. Morjani, M. Manfait
Primary Institution: Laboratoire de Spectroscopie Biomoleculaire, UFR de Pharmacie, Reims, France
Hypothesis
Can aclacinomycin A enhance the effectiveness of doxorubicin against drug-resistant K562 tumor cells?
Conclusion
Aclacinomycin A can partially reverse doxorubicin resistance in K562 cells by increasing the drug's accumulation in the nucleus.
Supporting Evidence
- Non-cytotoxic doses of aclacinomycin A increased the cytotoxic activity of doxorubicin against resistant K562 cells.
- Simultaneous exposure to aclacinomycin A and doxorubicin resulted in significant increases in intranuclear doxorubicin concentrations.
- The presence of aclacinomycin A partly blocks the efflux of doxorubicin in resistant cell nuclei.
Takeaway
This study shows that a drug called aclacinomycin A can help another drug, doxorubicin, work better against cancer cells that usually resist it.
Methodology
The study used microspectrofluorometry to measure intranuclear doxorubicin concentrations in sensitive and resistant K562 cells treated with doxorubicin and aclacinomycin A.
Potential Biases
Potential bias in the selection of drug concentrations and cell lines used.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
K562 human leukemia cell line, including both sensitive and doxorubicin-resistant variants.
Statistical Information
P-Value
p<0.001
Confidence Interval
null
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website